BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30080752)

  • 1. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
    Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
    J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.
    Tanaka T; Inamoto Y; Yamashita T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Tanosaki R; Fukuda T
    Biol Blood Marrow Transplant; 2016 May; 22(5):919-24. PubMed ID: 26785333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children.
    Masetti R; Vendemini F; Quarello P; Girardi K; Prete A; Fagioli F; Pession A; Locatelli F
    Pediatr Blood Cancer; 2020 May; 67(5):e28208. PubMed ID: 32065469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
    Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation.
    Yuan C; Boyd AM; Nelson J; Patel RD; Varela JC; Goldstein SC; Ahmad S; Zhu X; Mori S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1320-1324. PubMed ID: 30710685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.
    Maximova N; Zanon D; Rovere F; Maestro A; Schillani G; Paparazzo R
    Int J Hematol; 2015 Nov; 102(5):626-32. PubMed ID: 26084627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
    Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.
    Fujimi A; Kamihara Y; Hashimoto A; Kanisawa Y; Nakajima C; Hayasaka N; Yamada S; Okuda T; Minami S; Ono K; Iyama S; Kato J
    Int J Hematol; 2015 Oct; 102(4):471-6. PubMed ID: 25964100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience.
    Kilic Gunes E; Yigit Kaya S; Yaman F; Yeniay MK; Vural K; Comert M; Sevindik OG; Andic N; Dagdas S; Nizam Ozen I; Kaynar L; Yavasoglu F; Ozet G; Karakus V; Ayli M
    Leuk Res; 2024 May; 140():107484. PubMed ID: 38520796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
    Depré F; Aboud N; Mayer B; Salama A
    Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation.
    Rivera D; Bastida JM; Lopez-Corral L; Sanchez-Guijo F; Cabrero M; Martin A; Perez E; Lopez-Parra M; Avendaño A; Veiga A; Baile M; Arratibel N; Carrillo J; Vazquez L; Caballero MD; Gonzalez-Porras JR
    Bone Marrow Transplant; 2019 May; 54(5):757-761. PubMed ID: 30356164
    [No Abstract]   [Full Text] [Related]  

  • 17. Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series.
    Lancman G; Coltoff A; Steinberg A
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):171-174. PubMed ID: 30030975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has Eltrombopag eliminated the need to use allogeneic HSCT in first line treatment of pediatric aplastic anemia?
    Huan Ng C; Jang-Milligan F; Schultz KR
    Pediatr Hematol Oncol; 2021 Aug; 38(5):417-419. PubMed ID: 34157932
    [No Abstract]   [Full Text] [Related]  

  • 19. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
    Suntsova EV; Demina IM; Ignatova AA; Ershov NM; Trubina NM; Dobrynina J; Serkova IV; Supik ZS; Orekhova EV; Hachatryan LA; Kotskaya NN; Pshonkin AV; Maschan AA; Novichkova GA; Panteleev MA
    Int J Hematol; 2017 Jun; 105(6):841-848. PubMed ID: 28271416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience.
    Yaman Y; Elli M; Şahin Ş; Özdilli K; Bilgen H; Bayram N; Nepesov S; Anak S
    Pediatr Transplant; 2021 Aug; 25(5):e13962. PubMed ID: 33452850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.